Expert Interview
Discussing the potential use of Sanofi and AstraZeneca’s newly approved RSV antibody drug for infants, nirsevimab, with a Pediatric Emergency Room Physician
Ticker(s): SNY, AZNInstitution: Holy Redeemer Hospital
- Pediatric Emergency Medicine, Chair of the Department of Pediatrics, Director of Monoclonal Antibody Infusion Program, and Medical Director of the COVID19 Monoclonal Antibody Infusion Program
- treats 30 pediatric patients for SARS-CoV-2 per week on average; higher during surges and lower when post surge
- has prescribed Veklury and Paxlovid to high risk pediatric patients, having prescribed over 100 doses and counting so far.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
